New Male Contraception Offered
JACKSONVILLE, Fla., April 1 /PRNewswire/ -- Pro-Vas is the first male contraceptive procedure, other than condoms or vasectomy, to provide effective affordable birth control for men and it is available to physicians across the United States immediately.
Pro-Vas is the creation of MenRx Surgical, a Gyrx LLC portfolio company, and its CEO, Bill Dennis, a highly successful Jacksonville-based corporation and is FDA approved. Dennis has more than 30 U.S. and international patents and patents pending with a track record of bringing cutting edge medical products and solutions to market. "Pro-Vas is the most exciting innovation yet. When men and their doctors understand the simplicity and effectiveness of the device, I think it will completely change the way we think about male birth control," said Dennis.
The simple procedure, performed comfortably in a doctor's office with no general anesthesia effectively "ligates" the vas deferens with a small implantable titanium spring clip, stopping the flow of sperm. The no scalpel procedure takes 15 minutes or less with little post procedural pain. This is in stark contrast to the traditional vasectomy, which cuts, sutures or cauterizes the vas deferens and, most importantly, Pro-Vas is reversible with a standard vasovasostomy procedure. Most men notice no change in their sex drive after the Pro-Vas procedure.
Pro-Vas was specifically developed to address
- Increased male birth control accountability and alternatives
- Decreased post surgical complications of traditional vasectomies
- Reduce vasectomy post procedural pain
"Men today have few contraception options and our culture and advertisers have placed the birth control burden largely on women. Pro-Vas offers an easy, effective alternative. I think it has the potential to change the way men and women look at birth control," said Bill Dennis, MenRx Surgical's CEO.
For more information, please go to www.pro-vas.com or contact Bill Dennis 904-641-2599, firstname.lastname@example.org.
SOURCE Gyrx LLC